Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bruker reports robust 2022 performance, eyes growth amid challenges

Bruker's strong financial performance in 2022, driven by organic revenue growth and strategic investments, positions the company for continued success.
While facing supply chain challenges and geopolitical risks, Bruker remains optimistic about growth opportunities in proteomics and spatial biology.
Confidence in 2023 outlook is supported by strong bookings, backlog visibility, and expectations of solid organic growth in key markets.

Bruker reports strong Q1 earnings, eyes spatial biology markets

Bruker's Q1 2023 performance showcased robust revenue growth and margin improvement, with strong demand across key segments and regions.
While facing challenges like margin declines and supply chain constraints, the company is well-positioned to capitalize on opportunities in spatial biology and proteomics markets.
By focusing on innovation, capacity investments, and addressing backlog delays, Bruker aims to sustain growth momentum and meet future demand expectations.
Overall, Bruker's strategic initiatives and market positioning indicate a positive outlook for continued growth and market leadership in the analytical instruments industry.

Bruker reports strong Q2 earnings, eyes global growth opportunities

Bruker's Q2 2023 performance reflects strong revenue and EPS growth, driven by demand across key segments and regions. The company's focus on innovation and global expansion positions it well for future growth.
While facing challenges such as high lead times and supply chain issues, Bruker is proactively managing costs and investing in capacity to meet demand. Opportunities for organic growth and profitability through strategic investments and pricing trends are on the horizon.
Overall, Bruker's Q2 2023 earnings call highlights a resilient performance, strategic strengths in R&D and global presence, challenges in capacity and logistics, and opportunities for sustained growth and profitability.

Bruker reports strong Q3 earnings and eyes sustainable growth

Bruker's Q3 2023 performance reflects robust revenue and earnings growth, supported by strong organic growth and strategic acquisitions.
While facing challenges in biopharma investments and China trends, Bruker's strengths lie in its elevated backlog and growth opportunities in green tech and academic funding.
The company's focus on high-end Life Science tools in China and long-term growth prospects position it well for sustained success.
Overall, Bruker's performance in Q3 2023 showcases resilience and strategic positioning for future growth.

Bruker excels in Q4 2023, eyes accelerated growth and acquisitions

Bruker's strong Q4 2023 performance showcased robust revenue and EPS growth, though challenges like margin pressure and geopolitical risks persist. With a focus on strategic acquisitions and market opportunities, Bruker aims for continued growth and innovation.

Bruker boosts revenue guidance after Q1 growth, faces margin challenges

Bruker's Q1 2024 performance showed growth despite margin challenges, with increased revenue guidance for the year.
Strong geographic revenue growth in the Americas and Europe contrasted with a decline in Asia Pacific.
Strategic acquisitions and focus on organic growth present opportunities for Bruker in 2024.
Challenges include margin compression, dilution from integration, and lower organic growth due to order distortions.

Bruker reports robust Q2 earnings, eyes growth in key sectors

Bruker's strong Q2 performance and strategic acquisitions are driving growth in key areas like spatial biology and molecular diagnostics.
While facing margin challenges due to recent acquisitions, the company remains confident in achieving operational excellence and margin expansion.
Maintaining mid-single-digit organic revenue growth and focusing on operational efficiency position Bruker for continued success in the market.
The company's outlook remains positive with opportunities for growth through acquisitions and market demand for its innovative solutions.

Bruker reports strong Q3 earnings, eyes margin expansion in 2025

Bruker's Q3 '24 performance was strong, with revenue growth and margin improvements.
Challenges include weaker-than-expected demand in biopharma and China markets.
Anticipated opportunities lie in margin expansion and innovative solutions in 2025.
Focus on driving improvements in acquired businesses to drive growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Bruker (BRKR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Bruker (BRKR) Ahead of Earnings?

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Bruker (BRKR) Keep the Earnings Surprise Streak Alive?

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2021 financial results on Monday, August 2, 2021, after the market closes. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2021 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide pres

Bruker Announces Date and Time of Second Quarter 2021 Earnings Release and Webcast

Bruker (BRKR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Bruker (BRKR) Is a Great Growth Stock

Bruker (BRKR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Bruker (BRKR) Hits 52-Week High, Can the Run Continue?

BILLERICA, Mass.--(BUSINESS WIRE)--At Bruker's virtual 4D-Metabolomics™ eXceed Symposium (eXceed Symposia 4D-Metabolomics 2021 | Bruker), Bruker Corporation (Nasdaq: BRKR) today announced the launch of a new VIP-HESI ion source to increase sensitivity dramatically, and new integrated software tools to increase confidence in 4D-Metabolomics and 4D-Lipidomics workflows. The heated VIP-HESI ion source enables sensitivity gains of up to 16-fold by efficient desolvation, enabling new applications ac

Novel 4D-Metabolomics and 4D-Lipidomics Workflows, Libraries and ML-based CCS Prediction Tools to Transform Metabolomics and Lipidomics

Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.

Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View

At its 2021 Virtual Investor Day, Bruker Corporation (NASDAQ: BRKR) raised the 2021 outlook boosted by its first-quarter solid performance. For 2021, Bruker expects revenue growth of approximately 16-18% Y/Y, up from the previously issued growth guidance of 14-16% in the Q1 earnings release.

Bruker Updates FY21 Guidance, Issues Medium Term Outlook

BILLERICA, Mass.--(BUSINESS WIRE)--At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company's strategy and Project Accelerate 2.0 initiatives, including the Company's potential high-growth opportunities in the areas of proteomics and spatial biology. Bruker will also update its fiscal year 2021 guidance and will discuss its medium term financial outlook through 2024. Fiscal Year (FY 2021) Guidance Update For fiscal year 2021, Bruker continues to project

Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day

Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.

Bruker (BRKR) FluoroType Assay Detects New SARS-CoV-2 Variants

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) will host a Virtual Investor Day on June 17th, 2021, starting at 10:00 AM Eastern Daylight Time. The Investor Day will be in a virtual format, with no option to attend in person. Bruker's Virtual Investor Day will provide a deeper look into the Company's strategies and Project Accelerate 2.0 initiatives and will feature presentations by the Executive Leadership Team, followed by a live Q&A session. Bruker also intends to c

Bruker to Host Virtual Investor Day on June 17th, 2021

NEHREN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the FluoroType SARS-CoV-2 varID Q assay – a quantitative LiquidArray® mid-plex PCR panel. This novel assay panel also detects several important mutations to enable laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The very sensitive FluoroType SARS-CoV-2 varID Q diagnostic test detects the SARS-CoV-2 virus using three independent gene targets f

Bruker Launches CE-IVD Quantitative Coronavirus Mid-Plex PCR Assay with Mutation Detection for Routine Variant Differentiation

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Why Is Bruker (BRKR) Up 0.5% Since Last Earnings Report?

BILLERICA, Mass.--(BUSINESS WIRE)--At Bruker's virtual 4D-Proteomics™ eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation (Nasdaq: BRKR) today announced the launch of two new timsTOF instruments. They further advance and enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, for example in cancer liquid biopsy research. Bruker's collaborators are making major progress in unbiased single c

Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth

Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Bruker (BRKR)

Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Bruker (BRKR)

IDEXX Laboratories

Inmode Ltd

Discovering new insights into Covid-19, particularly 'long Covid', InMode and Idexx peer Bruker continues to test new buy point. The post InMode, Idexx Peer Bruker Tests Buy Zone With New Insights Into 'Long Covid' appeared first on Investor's Business Daily.

InMode, Idexx Peer Bruker Tests Buy Zone With New Insights Into 'Long Covid'

Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.

Bruker's (BRKR) Research Tools Enable New insight on PACS

Bruker Corporation is a global developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions for use in the life (microscopic, molecular, and cellular) and material sciences. Bruker's product portfolio makes up ~82% of revenues (FYE 2020) and consists of various testing solutions used in microbiology/infectious diseases diagnostics (e.g. MALDI Biotyper rapid pathogen identification), amongst others.

Bruker: $500M Buyback And Promising New Markets Will Drive Value

PERTH, Australia--(BUSINESS WIRE)--A clinical research collaboration on COVID-19 pheno-conversion and subsequent pheno-reversion has discovered transient and persistent systemic changes of the molecular signatures in patient blood samples three months after the acute COVID-19 disease phase. These biochemical abnormalities, identified by a quantitative, label-free assay platform integrating nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), relate to ongoing ‘long COVID' s

Bruker's Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID' and Post-Acute Metabolic Abnormalities

Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

BILERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2021, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company's common stock over a two-year period commencing on May 13, 2021. The share repurchase authorization permits shares to be repurchased under open market purchases, accelerated share repurchases, or pursuant to trading plans intended to qualify under Rule 10b5-1 of the Se

Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board also Declares Quarterly Dividend

Continental Resources

Molina Healthcare

We have narrowed down our search to five growth stocks that have popped more than 25 % year to date and still have upside left for 2021. These are: UPS, CLR, MOH, CDW, and BRKR

Top 5 Growth Picks Amid Disappointing April Jobs Data

ETTLINGEN, Germany--(BUSINESS WIRE)--Nuclear magnetic resonance (NMR) spectroscopy has been incorporated by the intergovernmental and International Organization of Vine and Wine (OIV) in its compendium of International Methods of Analysis of Wines and Musts, for the quantification of six key parameters in wine – glucose, malic acid, acetic acid, fumaric acid, shikimic acid and sorbic acid. Traditionally, several analytical techniques with individual calibrations are needed to measure these para

International Organization of Vine and Wine (OIV) Officially Incorporates NMR Method in Compendium of International Methods of Analysis of Wines and Musts

Bruker Corporation (BRKR) CEO Frank Laukien on Q1 2021 Results - Earnings Call Transcript

News for Bruker Stock (BRKR)